Matsuda H, Takeda Y, Ueno T, Takeda R
Nihon Shokakibyo Gakkai Zasshi. 1989 Dec;86(12):2742-8.
In the present study, we have measured the serum concentration of PIIIP in patients with various liver diseases, and studied serial changes in serum PIIIP after TAE and its gel filtration pattern in 10 cases of hepatocellular carcinoma undergone TAE. The following results were obtained. 1) Serum concentration of PIIIP was 12.3 +/- 6.1 ng/ml in normal controls and elevated significantly in liver cirrhosis, liver cirrhosis with hepatocellular carcinoma, chronic active hepatitis, and acute hepatitis. 2) There was no significant difference in the serum concentrations of PIIIP between liver cirrhosis and liver cirrhosis with hepatocellular carcinoma. The result suggested that serum PIIIP cannot be a specific marker of hepatocellular carcinoma. However, the serum PIIIP concentration was decreased 2 or 4 weeks after TAE in effective cases, whereas increased in ineffective cases. Thus, the measurement of serial change in the serum PIIIP after TAE was considered to be useful for evaluating the effectiveness of TAE. 3) In analysing the elution patterns of serum PIIIP by gel chromatography, the peak of 125I-PIIIP antigen decreased 4 weeks after TAE in effective cases, whereas, no change was observed in the elution profile by gel chromatography 4 weeks after TAE in ineffective cases. These results seem to be caused by necrosis of hepatocellular carcinoma by TAE, and suggest the possibility that PIIIP is produced in hepatocellular carcinoma tissue.
在本研究中，我们测定了各种肝病患者血清中Ⅲ型前胶原肽（PIIIP）的浓度，并研究了10例接受经动脉栓塞化疗（TAE）的肝细胞癌患者TAE术后血清PIIIP的系列变化及其凝胶过滤模式。获得了以下结果。1）正常对照组血清PIIIP浓度为12.3±6.1 ng/ml，在肝硬化、肝硬化合并肝细胞癌、慢性活动性肝炎和急性肝炎中显著升高。2）肝硬化和肝硬化合并肝细胞癌患者血清PIIIP浓度无显著差异。结果表明血清PIIIP不能作为肝细胞癌的特异性标志物。然而，有效病例TAE术后2周或4周血清PIIIP浓度降低，而无效病例则升高。因此，TAE术后血清PIIIP系列变化的测定被认为有助于评估TAE的疗效。3）在通过凝胶色谱分析血清PIIIP的洗脱模式时，有效病例TAE术后4周125I-PIIIP抗原峰降低，而无效病例TAE术后4周凝胶色谱洗脱图谱未观察到变化。这些结果似乎是由TAE导致肝细胞癌坏死引起的，并提示PIIIP可能在肝细胞癌组织中产生。
